All In Biotech

Drug Trial Radar · NCT00004128

Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and the GIMEMA-ALWP

Last checked: Nov 19, 2026Latest source record: Dec 23, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,000

Planned (sponsor's estimate)

Start

Sep 1999

Primary completion

Jan 2008

Sponsor

Sponsor type
Research network
Collaborators
Gruppo Italiano Malattie EMatologiche dell'Adulto
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
All sexes, from 15 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Giving combination chemotherapy before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood or bone marrow and stored. More chemotherapy or radiation therapy is given prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation therapy. Interleukin-2 may stimulate the patient's white blood cells to kill cancer cells. PURPOSE: This randomized phase III trial is studying two different regimens of combination chemotherapy, interleukin-2, and peripheral stem cell transplant and comparing them to see how well they work in treating patients with acute myeloid leukemia.

Conditions

  • Leukemia

Interventions

  • aldesleukinBiological

  • filgrastimBiological

  • busulfanDrug

  • cyclophosphamideDrug

  • cytarabineDrug

  • daunorubicin hydrochlorideDrug

  • etoposideDrug

  • autologous bone marrow transplantationProcedure

  • peripheral blood stem cell transplantationProcedure

  • radiation therapyRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of overall survival and disease-free survival after first randomization
  2. Duration of overall survival and disease-free survival after second randomization

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.